Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

The Good, the Bad, and the Different: A Primer on Aspects of Heterogeneity of Treatment Effects

JMCP June 2014 cover

Each person is unique thanks to a multitude of factors, such as racial and ethnic backgrounds, age, genetics, chronic conditions, disease severity, gender, environment, and even personal preferences. These and other factors make patients different and affect how they may respond to a certain treatment. 

When there are differences in how different patients respond to treatments it is known as individual treatment effects (or heterogeneity). Because not all patients respond the same way to the same treatment, health care decisions that are made based on a "one-size-fits-all" model could lead to “substantial benefits for some patients, little benefit for many and harm for a few patients.”

But when are these differences meaningful? When is more flexibility needed in coverage policies and when are fewer treatment choices appropriate to provide quality health care and manage health care costs? What information is needed to evaluate when individual treatment effects or heterogeneity exists?  This concept of heterogeneity is explained and further explored via four articles published in the June 2014 issue of the Journal of Managed Care & Specialty Pharmacy:

The Good, the Bad, and the Different: A Primer on Aspects of Heterogeneity of Treatment Effects
Authors: Malone DC; Hines LE, Graff JS.
This article explains the concept of heterogeneity and its importance, especially for clinicians and pharmacy and therapeutics committee members who are making clinical, coverage and reimbursement decisions at a population level. The article also presents a variety of tools and resources to aid decision-makers as they evaluate studies to determine when clinically relevant differences exist. In particular, the article outlines two checklists, one to help decision-makers review patient differences within a study, and the other to help decision-makers understand patient differences across studies.

Managing Heterogeneity in Prescription Drug Coverage Policies
Author:  Teagarden JR.
Necessity and fairness require that health plans limit the products and services they cover, and the basis for plans’ decisions refers to population averages and related population parameters. However, individuals vary and may not be accurately represented by the parameters used to establish coverage policies. Health plans, therefore, are obligated to anticipate and manage heterogeneity among their member groups. This commentary offers considerations for managing heterogeneity in prescription drug benefits.

Medical and Pharmacy Coverage Decision Making at the Population Level
Authors: Mohr PE, Tunis SR.
Medicare is one of the largest health care payers in the United States. As a result, its decisions about coverage have profound implications for patient access to care. In this commentary, which includes a case study, the authors describe how Medicare used evidence on heterogeneity of treatment effects to make population-based decisions on health care coverage for implantable cardiac defibrillators. This case study is discussed in the context of the rapidly expanding availability of comparative effectiveness research. While there is a potential tension between population-based and patient-centered decision making, the expanded diversity of populations and settings included in comparative effectiveness research can provide useful information for making more discerning and informed policy and clinical decisions.

Evaluation of an Educational Program on Deciphering Heterogeneity for Medical Coverage Decisions
Authors: Warholak TL, Hilgaertner JW, Dean JL, Taylor AM, Hines LE, Hurwitz J, Brown M, Malone DC.
The University of Arizona College of Pharmacy conducted an evaluation of its seminar series, funded by NPC, on the important role of heterogeneity in influencing treatment outcomes and in evaluating evidence for making critical drug therapy decisions. This study found that this educational program was effective in improving participants’ knowledge of heterogeneity concepts and methods to evaluate heterogeneity.

To illustrate the challenges with heterogeneity, NPC has developed two infographics, one to help patients understand the concept, and the other to help health professionals in their evaluation of studies.

Blog Post

ASCO’s Clinical Pathways Recommendations and Remaining Challenges

The American Society of Clinical Oncology (ASCO) today released its “policy statement on clinical pathways in oncology,” which acknowledges the...
Blog Post

#TBT: “Talk About Your Medicines” Month & A Question Checklist for Patients

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research...
Blog Post

How Can We Assess the Value of a Companion Diagnostic Test?

When President Obama pledged $215 million for a Precision Medicine Initiative during his State of the Union address earlier this year, he...
Blog Post

#TBT: Men’s Health Month & Differences in Prostate Cancer Treatment

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Press Release

Michael Ciarametaro Joins National Pharmaceutical Council as Director of Research

Washington, DC (July 31, 2014)—The National Pharmaceutical Council (NPC) today announced that Michael Ciarametaro has joined the health policy...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Press Release

National Pharmaceutical Council Comments on PCORI Approval of Research Methodology Standards

Washington, DC (November 19, 2012)—The National Pharmaceutical Council (NPC) today commented on the Patient-Centered Outcomes Research Institute’s (...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

The Risks of Standardized Health Care

Think about the last time you visited a medical office. Even at a specialist’s office, chances are that each person waiting for his or her name to be...
Commentary and Testimony Page

When the Sound Bite Doesn’t Tell the Full Story

Not long ago, President Obama was asked at a press conference about comparative effectiveness research (CER) and how it fits into the health care...
YouTube Videos

Taking Patient Variations Into Account

Dr. Lisa Egbuonu-Davis, founder of ROI Squared, explains that data is generally designed toward looking at the mean differences instead of the...
YouTube Videos

Dr. Allison-Ottey on Individualized Patient Care

Dr. Sharon Allison-Ottey, executive director of the COSHAR Foundation, explains that when it comes to ensuring optimal care for patients, all of...
YouTube Videos

Payer Views of Individualized Health Care

Dr. Daniel Malone, professor at the University of Arizona School of Pharmacy, explains how payers view the issue of individualized therapy. He says...
YouTube Videos

Dr. Puckrein on the Issue of Individual Patient Differences

Dr. Gary Puckrein, founder and president of the National Minority Quality Forum, says that there is tremendous variability in how different patients...
Blog Post

ASCO’s Clinical Pathways Recommendations and Remaining Challenges

The American Society of Clinical Oncology (ASCO) today released its “policy statement on clinical pathways in oncology,” which acknowledges the...
Blog Post

#TBT: “Talk About Your Medicines” Month & A Question Checklist for Patients

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research...
Blog Post

How Can We Assess the Value of a Companion Diagnostic Test?

When President Obama pledged $215 million for a Precision Medicine Initiative during his State of the Union address earlier this year, he...
Blog Post

#TBT: Men’s Health Month & Differences in Prostate Cancer Treatment

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
  •  
  • 1 of 3
  • >